A TfRMAb-GDNF fusion protein was administered every other day at an ID of 1 mg/kg for 3 weeks via IV injection in a 6-hydroxydopamine model of PD in the mouse, and this treatment resulted in a 272% increase in striatal tyrosine hydroxylase (TH) enzyme activity that correlated with a 45% reduction in abnormal motor behavior induced by either apomorphine or amphetamine (Fu et al, 2010). The gene discussed is TH; the disease is Parkinson disease.